Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Trial Provides Proof-of-Concept for Cell-Based Therapy in a Myelination Disorder Company to Host Conference Call Today to Discuss Summary Results NEWARK, Calif., April 2, 2012 (GLOBE NEWSWIRE)...
-
NEWARK, Calif., March 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it will host a conference call and webcast to discuss results from its Phase I clinical trial in...
-
NEWARK, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) and genOway (NYSE:ALGEN) announced today that they have entered into a license agreement under which StemCells has...
-
NEWARK, Calif., March 13, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
-
NEWARK, Calif., March 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
-
NEWARK, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Rodney Young, Chief Financial Officer, will present an update on the Company's programs and...
-
NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is...
-
NEWARK, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at...
-
NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical...
-
NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data demonstrating that its proprietary HuCNS-SC® cells (purified...